Search Results - "диффузная в-клеточная крупноклеточная лимфома"

1

Academic Journal

КЛИНИЧЕСКИЕ АСПЕКТЫ ПОРАЖЕНИЯ НЕРВНОЙ СИСТЕМЫ ПРИ НЕХОДЖКИНСКИХ ЛИМФОМАХ В СТАРШИХ ВОЗРАСТНЫХ ГРУППАХ

Source: University Therapeutic Journal, Vol 5, Iss 4 (2024)

Subject Terms: интраваскулярная лимфома, первичная диффузная В-клеточная крупноклеточная лимфома центральной нервной системы, неходжкинская лимфома, Medicine, нейролимфоматоз, первичная лимфома глаза

Access URL: https://doaj.org/article/eea75ceaf38f4c9d9ee31305d0250520

View record at OpenAIRE

2

Academic Journal

Lymphoproliferative tumors in rheumatic diseases ; Лимфопролиферативные опухоли при ревматических болезнях

Authors: V. R. Gorodetskiy, I. V. Poddubnaya, E. L. Nasonov, В. Р. Городецкий, И. В. Поддубная, Е. Л. Насонов

Source: Rheumatology Science and Practice; Vol 62, No 6 (2024); 575-581 ; Научно-практическая ревматология; Vol 62, No 6 (2024); 575-581 ; 1995-4492 ; 1995-4484

Subject Terms: патогенез, rheumatic disease, T cell large granular lymphocytic leukemia, Felty’s syndrome, diffuse large B cell lymphoma, pathogenesis, ревматическое заболевание, T клеточный лейкоз из больших гранулированных лимфоцитов, синдром Фелти, диффузная В клеточная крупноклеточная лимфома

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3652/2413; Ekström Smedby K, Vajdic CM, Falster M, Engels EA, MartínezMaza O, Turner J, et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi:10.1182/blood-2007-10-119974; Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069-2077. doi:10.1158/1055-9965.EPI-06-0300; Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60. doi:10.1093/jnci/djj004; Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2001;27(4):750-756. doi:10.1006/bcmd.2001.0442; Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-134. doi:10.1097/01.bor.0000209423.39033.94; Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study. Ann Oncol. 2014;25(10):2025-2030. doi:10.1093/annonc/mdu365; Kitamura W, Asada N, Tabata T, Shibata R, Nishi T, Kato Y, et al. Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. J Clin Exp Hematop. 2022;62(1):35-40. doi:10.3960/jslrt.21010; Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, et al. Large granular lymphocytic leukemia – A retrospective study of 319 cases. Am J Hematol. 2021;96(7):772-780. doi:10.1002/ajh.26183; Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on 229 cases. Haematologica. 2010;95(9):1534-1541. doi:10.3324/haematol.2009.018481; Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.; Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. Leuk Res. 2020;90:106299. doi:10.1016/j.leukres.2020.106299; Schwaneck EC, Renner R, Junker L, Einsele H, Gadeholt O, Geissinger E, et al. Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: A comprehensive analysis of 529 patients. Arthritis Rheumatol. 2018;70(12):1914-1922. doi:10.1002/art.40654; Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016;139(Pt 5):1348-1360. doi:10.1093/brain/aww024; Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi:10.1093/rheumatology/keab716; Quintanilla-Martinez L, Fend F. Turning up the heat on salivary gland MALT lymphoma. Blood. 2022;139(14):2094-2096. doi:10.1182/blood.2021012624; Насонов ЕЛ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: перспективы. Терапевтический архив. 2022;94(5):605-609. doi:10.26442/00403660.2022.05.201501; Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60(12):2971-2978. doi:10.1002/1097-0142(19871215)60:123.0.co;2-o; Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood. 1997;89(1):256-260.; Cheon H, Dziewulska KH, Moosic KB, Olson KC, Gru AA, Feith DJ, et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep. 2020;15(2):103-112. doi:10.1007/s11899-020-00565-6; Narváez J, Domingo-Domenech E, Gómez-Vaquero C, LópezVives L, Estrada P, Aparicio M, et al. Biological agents in the management of Felty’s syndrome: A systematic review. Semin Arthritis Rheum. 2012;41(5):658-668. doi:10.1016/j.semarthrit.2011.08.008; Shipley E, Héraud A, Hennette A, Vernhes JP. Efficacy of rituximab in Felty’s syndrome. Joint Bone Spine. 2008;75(5):621-622. doi:10.1016/j.jbspin.2008.02.018; Wang CR, Chiu YC, Chen YC. Successful treatment of refractory neutropenia in Felty’s syndrome with rituximab. Scand J Rheumatol. 2018;47(4):340-341. doi:10.1080/03009742.2017.1334816; Proc K, Madej M, Wiland P, Sebastian A. Biological treatment in Felty’s syndrome with profound neutropenia. Reumatologia. 2023;61(3):213-218. doi:10.5114/reum/167472; Gorodetskiy VR, Sidorova YV, Kupryshina NA, Vasilyev VI, Probatova NA, Ryzhikova NV, et al. Analysis of a single-institution cohort of patients with Felty’s syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatol Int. 2021;41(1):147-156. doi:10.1007/s00296-020-04757-4; Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20(5):245-266. doi:10.1016/j.blre.2006.01.003; Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362. doi:10.1172/JCI9940; Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018;109(4):926-933. doi:10.1111/cas.13525; Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27(7):1598-1600. doi:10.1038/leu.2012.350; Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048- 3057. doi:10.1182/blood-2012-06-435297; Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmä- ki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905- 1913. doi:10.1056/NEJMoa1114885; Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74-81. doi:10.1016/j.humpath.2017.12.014; Wegscheider C, Ferincz V, Schöls K, Maieron A. Felty’s syndrome. Front Med (Lausanne). 2023;10:1238405. doi:10.3389/fmed.2023.1238405; Gorodetskiy V, Sidorova Y, Biderman B, Kupryshina N, Ryzhikova N, Sudarikov A. STAT3 mutations in “gray-zone” cases of T-cell large granular lymphocytic leukemia associated with autoimmune rheumatic diseases. Front Med (Lausanne). 2022;9:1000265. doi:10.3389/fmed.2022.1000265; Armstrong RD, Fernandes L, Gibson T, Kauffmann EA. Felty’s syndrome presenting without arthritis. Br Med J (Clin Res Ed). 1983;287(6405):1620. doi:10.1136/bmj.287.6405.1620; Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1(3):257-259.; Fitzgerald P, O’Brien AA, Daly PA. Felty’s syndrome presenting with severe extra-articular features in the absence of clinical rheumatoid arthritis. Ir Med J. 1984;77(12):397-398.; Rozin A, Hoffman R, Hayek T, Balbir-Gurman A. Felty’s syndrome without rheumatoid arthritis? Clin Rheumatol. 2013;32(5):701-704. doi:10.1007/s10067-012-2157-3; Marchand T, Lamy T. The complex relationship between large granular lymphocyte leukemia and rheumatic disease. Expert Rev Clin Immunol. 2024;20(3):291-303. doi:10.1080/1744666X.2023.2292758; Moosic KB, Ananth K, Andrade F, Feith DJ, Darrah E, Loughran TP Jr. Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front Oncol. 2022;12:869205. doi:10.3389/fonc.2022.869205; Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468(7322):447-451. doi:10.1038/nature09518; Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol. 2018;30(1):72-78. doi:10.1097/BOR.0000000000000452; Romero V, Fert-Bober J, Nigrovic PA, Darrah E, Haque UJ, Lee DM, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med. 2013;5(209):209ra150. doi:10.1126/scitranslmed.3006869; Hohlfeld R, Schulze-Koops H. Cytotoxic T cells go awry in inclusion body myositis. Brain. 2016;139(Pt 5):1312-1314. doi:10.1093/brain/aww053; Поддубная ИВ, Бабичева ЛГ, Барях ЕА. Диффузная В-клеточная крупноклеточная лимфома: штрихи к эпидемиологическому портрету. Современная онкология. 2023;25(3):342- 345.; Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005:260-266. doi:10.1182/asheducation-2005.1.260; Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): A clinicopathologic study of 24 Japanese cases. Int J Surg Pathol. 2006;14(1):43-48. doi:10.1177/106689690601400108; Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, et al. B-cell lymphoma associated with Sjögren’s syndrome among Japanese patients: A clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop. 2009;49(2):89-95. doi:10.3960/jslrt.49.89; Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20-28. doi:10.1111/ejh.12116; Gorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi:10.1007/s00296-019-04470-x; Kiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer ME, Weber M, et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019;186(3):448-459. doi:10.1111/bjh.15953; Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207. doi:10.1200/JCO.2010.30.0368; Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594. doi:10.1200/JCO.2007.15.9277; Ichiki A, Carreras J, Miyaoka M, Kikuti YY, Jibiki T, Tazume K, et al. Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier. J Clin Exp Hematop. 2017;57(2):54-63. doi:10.3960/jslrt.17029; Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, et al. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget. 2015;6(21):18374-18388. doi:10.18632/oncotarget.4073; Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688-1697. doi:10.1038/modpathol.2017.93; Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217. doi:10.1111/j.1365-2559.2008.03076.x; Насонов ЕЛ. Достижения ревматологии в XXI в. Научно-практическая ревматология. 2014;52(2):133-140.

Availability: https://rsp.mediar-press.net/rsp/article/view/3652
https://doi.org/10.47360/1995-4484-2024-575-581

View record from BASE

3

Academic Journal

Mutation profile of diffuse large B-cell lymphoma with relapses in the central nervous system ; Мутационный профиль диффузной В-крупноклеточной лимфомы с рецидивами в центральной нервной системе

Authors: Voropaeva E.N., Pospelova T.I., Karpova V.S., Churkina M.I., Vyatkin Y.V., Ageeva T.A., Maksimov V.N.

Contributors: The work was performed with the financial support of the grant of the President of the Russian Federation to young scientists MD-2706.2019.7. The work was carried out within the framework of the budget topic under the State task No. AAAAA-A17-117112850280-2., Работа выполнена при финансовой поддержке гранта Президента РФ молодым ученым МД-2706.2019.7. Работа выполнена в рамках бюджетной темы по Государственному заданию № АААА-А17-117112850280-2.

Source: Advances in Molecular Oncology; Vol 9, No 3 (2022); 69-84 ; Успехи молекулярной онкологии; Vol 9, No 3 (2022); 69-84 ; 2413-3787 ; 2313-805X

Subject Terms: lymphoma, mutational profile, high-throughput sequencing, relapse, NF-kB signaling pathway, JAK-STAT signaling pathway, ТР53 gene, chromatin remodeling, immunological control, diffuse large B-cell lymphoma, central nervous system, лимфома, мутационный профиль, высокопроизводительное секвенирование, рецидив, сигнальный путь NF-kB, сигнальный путь JAK-STAT, ген ТР53, ремоделирование хроматина, иммунологический контроль, центральная нервная система, диффузная в-клеточная крупноклеточная лимфома